CTNNB1

Open Access
Compound #41 Targets Acute Myelogenous Leukemia by Inhibiting the Wnt/β-catenin Signaling Pathway
YUKI HADATE, YASUNAO HATTORI, YUKI TODA, SHIGEKUNI HOSOGI, SEIJI OKADA, YOSHIHIRO HAYASHI and EISHI ASHIHARA

Anticancer Research November 2024, 44 (11) 4789-4799; DOI: https://doi.org/10.21873/anticanres.17305
You have access
RRM2 Is a CTNNB1 Transport Regulator Promoting Colon Cancer Progression
SUNG UNG MOON, JONG HYEON LEE, MASAUD SHAH, SUKJOON YOON and HYUN GOO WOO

Anticancer Research June 2024, 44 (6) 2471-2485; DOI: https://doi.org/10.21873/anticanres.17054
You have access
CTNNB1 Mutations in Ovarian Microcystic Stromal Tumors: Identification of a Novel Deletion Mutation and the Use of Pyrosequencing to Identify Reported Point Mutation
KIYONG NA, EUN KYUNG KIM, WONJUN JANG and HYUN-SOO KIM

Anticancer Research June 2017, 37 (6) 3249-3258;
You have access
Absence of Canonical WNT Signaling in Adult Renal Cell Tumors of Embryonal Origin
NINA KAERGER BILLFELDT, DANIEL BANYAI and GYULA KOVACS

Anticancer Research May 2016, 36 (5) 2169-2173;

Main menu